Pharmaceuticals News

TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. (“Seraxis”) today...

New non-human primate data show Coave's ligand-conjugated suprachoroidal vector, coAAV-SCS, achieved up to 120-fold higher retinal and RPE-choroid expression than existing AAV capsids Aflibercept...

HIGHLIGHTS Texas Ibogaine Research Corporation (“TIRC”), the wholly-owned Texas subsidiary of Psyence BioMed, enters manufacturing partnership with Benuvia Operations, LLC for the planned U.S....

—Supports BioCryst’s evolution toward a more disciplined R&D model centered on external innovation— RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals,...

ZUG, Switzerland, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS) a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet...

DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third...

VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21) Prespecified Co-Primary Immunogenicity Endpoints: In Adults 50 and...

Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites Further confirms resolution of FDA inspection-related...

MELBOURNE, Australia and OXFORD, United Kingdom, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for...

Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites Further confirms resolution of FDA inspection-related...